Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
March 14 2023 - 4:01PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
commercial-stage biopharmaceutical company primarily focused on
developing and commercializing products in various therapeutic
areas, including opioid overdose, allergy, respiratory and
inflammatory disease, today announced that it will host an investor
conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to
discuss its financial and operating results for the fourth quarter
and full year 2022 as well as provide a corporate update. The
company’s fourth quarter and full year 2022 financial results news
release is expected to be available after 1 p.m. PT on March 16,
2023, and on its website.
Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2022
Financial Results Conference Call Date: Thursday, March 16,
2023 Time: 2:00 p.m. PT (5:00 p.m. ET) U.S. Dial-in (Toll
Free): 1-877-423-9813 Toll/International Dial-in:
1-201-689-8573
David J. Marguglio, President and CEO of Adamis, will host the
call along with other members of the management team. The call is
open to the public and will provide an update on recent
developments, events that have taken place during the year, and
certain goals for future periods. Forward-looking statements
concerning expectations regarding future company performance may be
made during the conference call.
A live audio webcast of the conference call will also be
available via this link, with a replay available shortly after the
live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
opioid overdose, allergy, respiratory and inflammatory disease.
Company products approved by the FDA include ZIMHI® (naloxone)
Injection for the treatment of opioid overdose and
SYMJEPI® (epinephrine) Injection for use in the emergency
treatment of acute allergic reactions, including anaphylaxis. For
additional information about Adamis Pharmaceuticals, please
visit our website and follow us
on Twitter and LinkedIn.
Contact:
Adamis Investor Relations Robert Uhl Managing
Director ICR
Westwicke 619.228.5886 robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024